COVID spike protein S1 sub-unit from virus or vaccine (we can strongly infer from this report) induces fibrinogen resistant to fibrinolysis; predisposes to hypercoagulation and microclots in lungs

SOURCE:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380922/

‘show that spike protein may interfere with blood flow. Mass spectrometry also showed that when spike protein S1 is added to healthy PPP, it results in structural changes to β and γ fibrin(ogen), complement 3, and prothrombin. These proteins were substantially resistant to trypsinization, in the presence of spike protein S1. Here we suggest that, in part, the presence of spike protein in circulation may contribute to the hypercoagulation in COVID-19 positive patients and may cause substantial impairment of fibrinolysis. Such lytic impairment may result in the persistent large microclots we have noted here and previously in plasma samples of COVID-19 patients. This observation may have important clinical relevance in the treatment of hypercoagulability in COVID-19 patients.’